Factors that Influence Treatment Choices and Goals in Frontline LR-MDS
Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji et al, EHA 2024), and when luspatercept should be chosen as a first-line treatment, considering its use before or alongside transfusion; they also explore the impact of luspatercept on hemoglobin levels and quality of life (Oliva et al, EHA 2024; Santini et al, ASH 2024), and the key factors in selecting between available treatment options for initial anemia management.
- How does the mutational burden influence the duration of response in patients with LR-MDS in COMMANDS (Komrokji et al, EHA 2024)?
- In your opinion, when would you choose luspatercept as the first-line treatment option?
- What are your thoughts on luspatercept use before or even alongside transfusion?
- What would be an appropriate Hgb cutoff?
- With regards to treatment goals, how does first-line treatment with luspatercept influence Hgb level and quality of life (Oliva et al, EHA 2024; Oliva et al, ASH 2024; Santini et al, ASH 2024)?
- How does improvement in Hgb levels impact patient quality of life?
- With initial anemia treatment beyond transfusions, there are different options available including luspatercept.
- Are there any other factors or final considerations when choosing between options?
- Are there any other factors or final considerations when choosing between options?
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
